BASIC RESEARCH

Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries

Nuno M M Pires¹, Daniel Eefting¹, Margreet R de Vries¹, Paul H A Quax¹, J Wouter Jukema²

¹ TNO-Quality of Life, Gaubius Laboratory, Leiden, The Netherlands
² Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands

Correspondence to:
Professor J W Jukema
Department of Cardiology, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands; j.w.jukema{at}lumc.nl

Background: Drug-eluting stents (DES) have been introduced successfully in clinical practice to prevent post-angioplasty restenosis. Nevertheless, concerns about the safety of DES still exist.

Objective: To investigate the vascular pathology and transcriptional responses to sirolimus and paclitaxel in a murine model for restenosis on underlying diseased atherosclerotic arteries.

Methods: Atherosclerotic lesions were induced by placement of a perivascular cuff around the femoral artery of hypercholesterolaemic ApoE*3-Leiden transgenic mice. Two weeks later these cuffs were replaced either by sirolimus- or paclitaxel-eluting cuffs. The vascular pathological effects were evaluated after two additional weeks.

Results: Both anti-restenotic compounds significantly inhibited restenotic lesion progression on the atherosclerotic plaques. Vascular histopathological analyses showed that local delivery of sirolimus has no significant adverse effects on vascular disease. Conversely, high dosages of paclitaxel significantly increased apoptosis, internal elastic lamina disruption, and decreased medial and intimal smooth muscle cells and collagen content. Moreover, transcriptional analysis by real-time RT-PCR showed an increased level of pro-apoptotic mRNA transcripts (FAS, BAX, caspase 3) in paclitaxel-treated arteries.

Conclusions: Sirolimus and paclitaxel are effective in preventing restenosis. Sirolimus has no significant effect on arterial disease. In contrast, paclitaxel at high concentration demonstrated adverse vascular pathology and transcriptional responses, suggesting a narrower therapeutic range of this potent drug. Since the use of overlapping stents is becoming more common in DES technology, this factor is important, given that higher dosages of paclitaxel may lead to increased apoptosis in the vessel wall and, consequently, to a more unstable phenotype of the pre-existing atherosclerotic lesion.

Abbreviations: BCL, B cell lymphoma; DEC, drug-eluting cuff; DES, drug-eluting stent(s); IEL, internal elastic lamina; MMP, matrix metalloproteinase; PEC, paclitaxel-eluting cuff; SEC, sirolimus-eluting cuff; SM, smooth muscle; SMC, smooth muscle cell; TIMP, tissue inhibitor of metalloproteinase

Keywords: atherosclerosis; animal model; pathology; restenosis; stents

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Vascular pathology as a result of drug-eluting stents

Martin R Bennett
Heart 2007 93: 895-896. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Byrne, R A, Kufner, S, Tiroch, K, Massberg, S, Laugwitz, K-L, Birkmeier, A, Schulz, S, Mehilli, J, for the Intracoronary Stenting and Angiographic Re, (2009). Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 95: 1489-1494 [Abstract] [Full Text]  
• Kang, W C, Ahn, T H, Moon, C I, Han, S H, Shin, E K, Kim, J-S, Ko, Y-G, Choi, D, Jang, Y, Kim, B-K, Oh, S J, Jeon, D W, Yang, J-Y (2009). Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. Heart 95: 970-975 [Abstract] [Full Text]  
• Hassan, A. K.M., Bergheanu, S. C., Stijnen, T., van der Hoeven, B. L., Snoep, J. D., Plevier, J. W.M., Schalij, M. J., Jukema, J. W. (2009). Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 0: ehn553v1-9 [Abstract] [Full Text]  
• Rodriguez, C., Martinez-Gonzalez, J., Raposo, B., Alcudia, J. F., Guadall, A., Badimon, L. (2008). Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases. Cardiovasc Res 79: 7-13 [Abstract] [Full Text]  
• Aoki, J., Mintz, G. S., Weissman, N. J., Mann, J. T., Cannon, L., Greenberg, J., Grube, E., Masud, A.R. Z., Koglin, J., Mandinov, L., Stone, G. W. (2008). Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents: Insights From Serial Intravascular Ultrasound Analyses in the TAXUS-V and -VI Trials. J Am Coll Cardiol Intv 1: 161-167 [Abstract] [Full Text]  
• Bennett, M. R (2007). Vascular pathology as a result of drug-eluting stents. Heart 93: 895-896 [Abstract] [Full Text]